Coya Therapeutics, Inc.
COYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,078.4% | -36.6% | 13,111.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 99.8% | 95.8% | -1,921.9% | -99,154.1% |
| R&D Expenses | $0 | $4 | $0 | $0 |
| G&A Expenses | $0 | $3 | $0 | $0 |
| SG&A Expenses | $0 | $3 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$7 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -53.8% | -3,920.5% | -2,976.9% | -209,031.5% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.4% | -3,725.2% | -2,833.4% | -149,373.8% |
| EPS | -0.13 | -0.36 | -0.44 | -0.18 |
| % Growth | 63.9% | 18.2% | -144.4% | – |
| EPS Diluted | -0.13 | -0.36 | -0.44 | -0.18 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.2% | -3,721% | -2,974.2% | -208,681.1% |